MA37649B1 - Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées - Google Patents

Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Info

Publication number
MA37649B1
MA37649B1 MA37649A MA37649A MA37649B1 MA 37649 B1 MA37649 B1 MA 37649B1 MA 37649 A MA37649 A MA 37649A MA 37649 A MA37649 A MA 37649A MA 37649 B1 MA37649 B1 MA 37649B1
Authority
MA
Morocco
Prior art keywords
producing hydroxylated
compounds
cyclopenta
cyclopentylpyrimidine compounds
hydroxylated cyclopentylpyrimidine
Prior art date
Application number
MA37649A
Other languages
English (en)
Other versions
MA37649A1 (fr
Inventor
Travis Remarchuk
Jonathan W Lane
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA37649A1 publication Critical patent/MA37649A1/fr
Publication of MA37649B1 publication Critical patent/MA37649B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux procédés de fabrication et de purification de composés cyclopenta[d]pyrimidines hydroxylées, qui sont utiles pour le traitement de maladies telles que le cancer comme inhibiteurs de protéine kinase akt, comprenant le composé (s)-2-(4-chlorophényl)-1-(4-((5r,7r)-7-hydroxy-5-méthyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)pipérazin-1-yl)-3-(isopropylamino)propan-1-one.
MA37649A 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées MA37649B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Publications (2)

Publication Number Publication Date
MA37649A1 MA37649A1 (fr) 2016-06-30
MA37649B1 true MA37649B1 (fr) 2017-03-31

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37649A MA37649B1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Country Status (19)

Country Link
US (1) US9309204B2 (fr)
EP (1) EP2861583B1 (fr)
JP (1) JP6214636B2 (fr)
KR (1) KR20150020211A (fr)
CN (1) CN104487430B (fr)
AU (1) AU2013262568B2 (fr)
BR (1) BR112014028570A2 (fr)
CA (1) CA2873653A1 (fr)
DK (1) DK2861583T3 (fr)
ES (1) ES2588878T3 (fr)
HK (1) HK1208673A1 (fr)
IL (1) IL235714A0 (fr)
MA (1) MA37649B1 (fr)
MX (1) MX2014013865A (fr)
PL (1) PL2861583T3 (fr)
RU (1) RU2014151017A (fr)
SG (1) SG11201407613RA (fr)
SI (1) SI2861583T1 (fr)
WO (1) WO2013173736A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
RU2643146C2 (ru) 2012-05-17 2018-01-31 Дженентек, Инк. Способ получения аминокислотных соединений
CN112898210A (zh) 2013-11-15 2021-06-04 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
JP6434511B2 (ja) * 2013-11-27 2018-12-05 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． ジヒドロピリミジン誘導体およびその中間体の製造方法
CN107001287B (zh) * 2014-09-26 2020-09-04 豪夫迈·罗氏有限公司 用于制备(环戊并[d]嘧啶-4-基)哌嗪化合物的方法
EP4165026A1 (fr) 2020-06-16 2023-04-19 F. Hoffmann-La Roche AG Procédé de fabrication de composés de cyclopentylpyrimidine hydroxylée
KR20230035773A (ko) * 2021-09-06 2023-03-14 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (fr) 1993-12-12 1995-06-15 Yigal Cohen Nouveau procede servant a proteger des vegetaux des infections fongiques
EP0973396A4 (fr) 1997-04-07 2001-02-07 Merck & Co Inc Procede de traitement du cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
CA2363169A1 (fr) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibiteurs de la prenyle-proteine transferase
ATE296820T1 (de) * 1999-06-03 2005-06-15 Teikoku Hormone Mfg Co Ltd Substituierte pyrazol-derivate
WO2001022963A1 (fr) 1999-09-27 2001-04-05 Merck & Co., Inc. Procede de prevention de l'osteoporose
US7582766B2 (en) 2003-06-09 2009-09-01 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性２−アルキル−１，１，３−トリアルコキシカルボニルプロパンの製造方法
EP2173723B3 (fr) 2007-07-05 2014-11-19 Array Biopharma Inc. Pyrimidyl cyclopentanes utilsés comme inhibiteurs de la protéine kinase akt
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
RU2643146C2 (ru) 2012-05-17 2018-01-31 Дженентек, Инк. Способ получения аминокислотных соединений
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
WO2014071194A2 (fr) 2012-11-01 2014-05-08 Katz Robert S Méthodes de traitement de la fibromyalgie
CA2901577A1 (fr) 2013-02-18 2014-08-21 The Scripps Research Institute Modulateurs des recepteurs de la vasopressine a pouvoir therapeutique
EP2968318A4 (fr) 2013-03-15 2016-12-14 Shifa Biomedical Corp Composés anti-pcsk9 et méthodes de traitement et/ou de prévention de maladies cardio-vasculaires

Also Published As

Publication number Publication date
US20150099881A1 (en) 2015-04-09
KR20150020211A (ko) 2015-02-25
EP2861583B1 (fr) 2016-06-29
IL235714A0 (en) 2015-02-01
CA2873653A1 (fr) 2013-11-21
SG11201407613RA (en) 2015-01-29
CN104487430A (zh) 2015-04-01
PL2861583T3 (pl) 2016-12-30
JP6214636B2 (ja) 2017-10-18
BR112014028570A2 (pt) 2018-04-24
ES2588878T3 (es) 2016-11-07
EP2861583A1 (fr) 2015-04-22
MX2014013865A (es) 2015-05-07
MA37649A1 (fr) 2016-06-30
AU2013262568A1 (en) 2015-01-22
SI2861583T1 (sl) 2016-10-28
DK2861583T3 (en) 2016-10-03
US9309204B2 (en) 2016-04-12
JP2015518837A (ja) 2015-07-06
CN104487430B (zh) 2016-08-24
WO2013173736A1 (fr) 2013-11-21
HK1208673A1 (en) 2016-03-11
AU2013262568B2 (en) 2017-08-31
RU2014151017A (ru) 2016-07-10

Similar Documents

Publication Publication Date Title
MA37649A1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
BR112015021458A8 (pt) Processos e intermediários para preparar um inibidor de jak
MY196260A (en) Small Molecule Inhibitors of the Jak Family Of Kinases
PH12016502060A1 (en) Processes for preparing jak inhibitors and related intermediate compounds
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
MY161416A (en) 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
AU2016320892A8 (en) Salts of a Pim kinase inhibitor
NZ702513A (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
SG10201806450SA (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy